Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 2,845 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,845 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $23.38, for a total value of $66,516.10. Following the transaction, the chief financial officer directly owned 44,927 shares in the company, valued at $1,050,393.26. The trade was a 5.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Houte Hans Van also recently made the following trade(s):

• On Tuesday, May 5th, Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock. The shares were sold at an average price of $16.60, for a total value of $233,313.00.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock opened at $23.58 on Friday. The business has a fifty day simple moving average of $20.43 and a two-hundred day simple moving average of $17.81. Nurix Therapeutics, Inc. has a 1 year low of $8.19 and a 1 year high of $25.08. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of -6.83 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The company had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. As a group, equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Institutional Trading of Nurix Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC grew its position in shares of Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after purchasing an additional 1,190 shares in the last quarter. Intesa Sanpaolo Wealth Management acquired a new stake in shares of Nurix Therapeutics in the fourth quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Nurix Therapeutics in the fourth quarter valued at approximately $33,000. KBC Group NV bought a new stake in shares of Nurix Therapeutics in the first quarter valued at approximately $34,000. Finally, Wexford Capital LP acquired a new stake in Nurix Therapeutics during the third quarter worth approximately $41,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NRIX. HC Wainwright upped their price target on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Needham & Company LLC restated a “buy” rating and set a $34.00 price objective on shares of Nurix Therapeutics in a report on Friday, July 10th. Truist Financial upped their target price on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Oppenheimer initiated coverage on Nurix Therapeutics in a research note on Monday, June 29th. They set an “outperform” rating and a $28.00 target price on the stock. Finally, Wall Street Zen raised Nurix Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.00.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.